linjc16/ctgov huggingface dataset:
Ghrelin Levels in Early IVF Pregnancies

Study Overview
=================
Brief Summary
-----------------
In this study, we have assessed the potential prognostic value for gestational outcome of maternal ghrelin levels at very early stages of IVF pregnancies. In addition, ghrelin responses to meal intake were explored at early gestation.

Detailed Description
-----------------
Ghrelin is a pleiotropic hormone recently involved in the control of growth and metabolism, whose circulating levels fluctuate in relation to food intake and body mass index. Ghrelin has been detected in the decidualized endometrium, as well as in human and rat placenta, with a distinctive temporal pattern of expression along pregnancy. Comparison(s): A total of 106 patients undergoing IVF procedures were prospectively recruited. On d-16 and 23 after oocyte retrieval, the patients were subjected to blood sampling after overnight fasting, for determination of serum ghrelin, hCG and progesterone levels. In addition, ghrelin levels were assayed in these groups, 2-h after ingestion of a fixed-calorie meal.

Official Title
-----------------
Maternal Serum Ghrelin Levels in Early IVF Pregnancies: Lack of Prognostic Value for Gestational Outcome and Altered Post-Prandial Responses

Conditions
-----------------
Pregnancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing IVF

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ghrelin, Pregnancy outcome
Intraosseous Infusion for Neonatal Asphyxiated Resuscitation

Study Overview
=================
Brief Summary
-----------------
Intraosseous infusion is better than umbilical vein infusion for neonatal asphyxiated resuscitation

Official Title
-----------------
Intraosseous Infusion for Neonatal Asphyxiated Resuscitation

Conditions
-----------------
Asphyxia Neonatorum

Intervention / Treatment
-----------------
* Procedure: Intraosseous infusion
* Procedure: Umbilical vein infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: newborns who need resucitation Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 28 Weeks
Maximum Age: 42 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Umbilical vein infusion<br>using umbilical vein infusion for resucitation | Procedure: Umbilical vein infusion<br>* Using umbilical vein infusion for resustation in this group<br>|
| Experimental: Intraosseous infusion<br>using intraosseous infusion for resucitation | Procedure: Intraosseous infusion<br>* Using intraosseous infusion for resustation in this group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| success rate of resuscitation |  | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Injury of brain and heart |  | 1 month |
Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to test the usefulness of external magnetic stimulation (EMS) for treating the motor, cognitive, and neuropsychiatric symptoms of Parkinson's disease (PD). Participants with Parkinson's disease will be recruited at the PADRECC of the Philadelphia VA Medical Center. Enrolled participants will be randomly assigned to receive either active external magnetic stimulation or fake stimulation. The external magnetic stimulation is delivered by wearing a helmet that is embedded with many small circuits which produce a very small magnetic field around the head. The helmet is to be worn daily for two minutes immediately before bedtime for three months in a row. The helmet is for investigational use only and has not been approved for use by the FDA.

Detailed Description
-----------------
Current research seeks to provide a drug-free, non-invasive and non-toxic therapy for Parkinson's disease through transcranial magnetic stimulation (TMS) in the form of picoTesla magnetic therapy (pTMT). This therapy consists of an electronic device that emits magnetic flux densities that are more than ten million times lower than the magnetic flux density of the earth's magnetic field. Repetitive transcranial magnetic stimulation (rTMS) therapy aims to manipulate overall quality of life by improving motor function, as well as cognitive and neuropsychiatric symptoms such as depression.

Official Title
-----------------
Prospective Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease

Conditions
-----------------
Parkinson's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 40 to 80 years of age Diagnosis of possible or probable PD by the UK Brain Bank clinical diagnostic criteria Stable anti-Parkinsonian medical regimen for at least 30 days prior to enrollment Hoehn & Yahr Scale score of I to III No evidence of secondary or atypical Parkinsonism on MRI test in the past year Subjects are capable of giving informed consent Exclusion Criteria: Contraindications to MRI (e.g. cardiac pacemaker, claustrophobia, metal fragments or hardware within the orbit or cranium) History of stroke or TIA within the past year Dementia defined as a MMSE score < 25 Status post deep brain stimulation surgery Unstable medical conditions that would likely prevent the subject from completing the study

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's disease, Transcranial Magnetic Stimulation
Fabry's Disease and Pregnancy (PREFAB)

Study Overview
=================
Brief Summary
-----------------
Fabry's disease is a progressive systemic disease X-linked which combines neurological (Fabry's pain crises), dermatologic (angiokeratomas), renal (renal failure), cardiovascular (hypertrophic cardiomyopathy, valvular disease, conduction disorder, coronary heart disease) and cerebral vascular (stroke) symptoms . It is a glycosphingolipid metabolism disorder due to deficient or absent activity of the alpha-galactosidase A, causing accumulation of globotriaosylceramide in the lysosomes. The incidence is estimated being 1/40 000. Some patients suffering from Fabry's disease today are of childbearing age and their multidisciplinary care (by neurologists, obstetricians and anesthetists) raises several questions. About the anesthetic, the question of epidural block is debated in patients with neurological diseases and recommendations are not unequivocal. Indeed one of the problems of the management in those conditions is the potential worsening of the disease because of the anesthetic procedure. In addition, the possibility of an antiplatelet and / or an anticoagulant treatment in these patients may also contre-indicate an epidural block. The rate of epidural block achieved in patients with Fabry's disease is not currently known. Moreover, only sparse data on pregnancy outcomes in these patients are reported.

Official Title
-----------------
Description of Obstetrical Care, Mainly Anesthesic, in Patients With Fabry's Disease

Conditions
-----------------
Fabry's Disease, Pregnancy

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fabry's disease patients, aged 18 years or more, having had at least one childbirth Exclusion Criteria: Patient under a legal protection procedure Patient denying to participate to the study Lack of affiliation to a social security system

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaire|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of Fabry's disease patients having had an epidural block in childbirth. |  | The duration of the interview for this study with women with Fabry disease's will be one hour |
Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

Study Overview
=================
Brief Summary
-----------------
This study will assess the safety and efficacy of FA Intravitreal Inserts in subjects with macular edema secondary to RVO.

Official Title
-----------------
A Randomized, Double-masked, Pilot Study of the Safety and Efficacy of 0.5 µg/Day and 0.2 µg/Day Iluvien™ (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg in Subjects With Macular Edema Secondary to Retinal Vein Occlusion

Conditions
-----------------
Macular Edema, Retinal Vein Occlusion

Intervention / Treatment
-----------------
* Drug: Fluocinolone Acetonide
* Drug: Fluocinolone Acetonide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of macular edema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) Central subfield thickness > 300 μm BCVA of ≥ 24 and ≤ 68 letters Males and non-pregnant females 18 years and over Exclusion Criteria: Macular edema secondary to any condition other than RVO Presence of foveal atrophy, dense pigmentary changes or dense subfoveal exudates in the study eye Cystic intraretinal hemorrhage involving the fovea in the study eye that is responsible for vision loss Glaucoma or ocular hypertension (IOP > 21 mmHg or concurrent therapy at screening with IOP-lowering agents) Any prior treatment with intravitreal, subtenon, or periocular steroid or anti-VEGF therapy since the diagnosis of RVO in the study eye Any change in systemic steroid therapy within 3 months of screening History of vitrectomy in the study eye

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fluocinolone Acetonide 0.2 µg/day<br>0.2 µg/day | Drug: Fluocinolone Acetonide<br>* 0.2 µg/day<br>|
| Experimental: Fluocinolone Acetonide 0.5 µg/day<br>0.5 µg/day | Drug: Fluocinolone Acetonide<br>* 0.5 µg/day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Acuity | To compare the 3 month best corrected visual acuity to baseline in subjects diagnosed with macular edema secondary to retinal vein occlusion. BCVA will be measured according to the standard procedure developed for ETDRS at 4 meters or 3 meters if the electronic (E)-ETDRS system is employed. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Macular edema secondary to RVO
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the equivalence of JR-131 to Darbepoetin alfa and evaluate the safety of JR-131 in renal anemia patients with chronic kidney disease (CKD).

Conditions
-----------------
Anemia

Intervention / Treatment
-----------------
* Drug: JR-131
* Drug: Darbepoetin alfa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients being treated with Darbepoetin alfa. Exclusion Criteria: Patients having complication or history of a cardiovascular / lung / brain infarction. Patients having a pronounced hemorrhagic lesion.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: JR-131<br> | Drug: JR-131<br> <br> |
| Active Comparator: Darbepoetin alfa<br> | Drug: Darbepoetin alfa<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in Hemoglobin level |  | 24 weeks |
the Effect of Prenatal Vitamins on the Tooth Structure

Study Overview
=================
Brief Summary
-----------------
the effect of mother prenatal care on the teeth of the newborn children, if it affect the tooth structure or not

Detailed Description
-----------------
teeth lost due to normal shedding will be collected,it will be classified into mother that take pregnancy vitamins and mother that doesn't take pregnancy vitamins, the female will be from the same population and from the same city to make sure that the environmental condition are almost the same .teeth will be subjected to elementary analysis to determine the different ratio of different component and if there is any change between the two group

Official Title
-----------------
the Effect of Prenatal Vitamins on the Children Teeth: Elementary Analysis

Conditions
-----------------
Dental Caries

Intervention / Treatment
-----------------
* Other: intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria teeth lost due to normal shedding sound teeth with non hereditary conditions normal children mother that don not suffer from chronic illness ex: diabetes Exclusion Criteria: teeth extracted due to caries or trauma teeth with hereditary anomalies ex: hypoplasia

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| control<br>teeth of children of non vitamin taking mother | Other: intervention<br>* elementary analysis<br>|
| intervention<br>children teeth of vitamin taking mother | Other: intervention<br>* elementary analysis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the different teeth minerals and component | analysis of exofilated teeth mineral ratio | 3months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| caries index of chlidren | dmf index for every patient to count the total missed and decayed teeth | 3 months |
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Study Overview
=================
Brief Summary
-----------------
Randomized, double-blind, placebo-controlled investigating the efficacy of tradipitant in the treatment of motion sickness.

Official Title
-----------------
Motion Sifnos: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Conditions
-----------------
Motion Sickness

Intervention / Treatment
-----------------
* Drug: Tradipitant
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or non-pregnant, non-lactating female patients aged 18 - 75 years (inclusive); Body Mass Index (BMI) of ≥18 and ≤30 kg/m2; History or symptoms consistent with motion sickness Exclusion Criteria: Chronic nausea due to condition other than motion sickness; A positive test for drugs of abuse at the screening or evaluation visits; Clinically significant deviation from normal clinical laboratory results

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tradipitant<br> | Drug: Tradipitant<br>* Oral capsule<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Oral capsule<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in the incidence of vomiting | As measured by the Motion Sickness Severity Scale Motion Sickness Severity Scale (NRS 0-6); Lower score indicates improvement | 1 Day | 
| Improvement in the cardinal symptoms of motion sickness | As measured by the Motion Sickness Severity Scale Motion Sickness Severity Scale (NRS 0-6); Lower score indicates improvement | 1 Day |
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

Official Title
-----------------
68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors

Conditions
-----------------
Carcinoid Tumors, Islet Cell (Pancreatic NET), Other Neuroendocrine Tumors

Intervention / Treatment
-----------------
* Drug: 68Ga-DOTA TATE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Greater than 18 years-old at the time of radiotracer administration Provides written informed consent Known diagnosis of NET or suspected SSTR positive tumors by 111In-Octreotide scan, 18FDG-PET, or MRI of the abdomen when clinically indicated Karnofsky score greater than 50 or ECOG Performance Status 0-2 Women of childbearing age must have a negative pregnancy test at screening/baseline Able to remain still for duration of each imaging procedure (about one hour) Exclusion Criteria: Less than 18 years-old at the time of radiotracer administration Pregnant or nursing Serum creatinine >3.0 mg/dL Hepatic enzyme levels more than 5 times upper limit of normal. Use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments. Inability to lie still for the entire imaging time Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: 68Ga-DOTA TATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Obese Patients With Untreated Dyslipidemias

Study Overview
=================
Brief Summary
-----------------
To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with untreated dyslipidemia

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study of Weight-Reducing Effect and Safety in Obese Patients With Untreated Dyslipidemias

Conditions
-----------------
Obesity, Dyslipidemia

Intervention / Treatment
-----------------
* Drug: Rimonabant (SR141716)


Participation Criteria
=================
Eligibility Criteria
-----------------
BMI must be greater than 27 and less than 40 Patients with untreated dyslipidemia Stable weight (variation of less than 5 kg within 3 months prior to screening visit)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rimonabant (SR141716)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in body weight at 1 year. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolic parameters |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity